Fig. 3

The relationship between BCAR4 and miR-644a and the expression of BCAR4 in breast cancer patients and cells. A The predicted binding sites of BCAR4 and miR-644a from StarBase V3.0. The mutated binding sites were indicated. B, C, D, E, F, and G Luciferase reporter assay in HEK-293T, MDA-MB-231, and MCF-7. Cells were cotransfected with pRL-TK carrying wildtype or mutant binding site and the miR-644a mimic or the miR-644a inhibitor, and the luciferase activity was measured 48 h posttransfection. H RT-qPCR assay for miR-644a expression in MCF-7 and MDA-MB-231 transfected with BCAR4 siRNA and control. I RT-qPCR assay for miR-644a expression in plasma from 80 breast cancer patients and 80 healthy controls. J Pearson assay for the correlation between BCAR4 and miR-644a. K RT-qPCR assay for miR-644a expression in breast cancer cell lines and the noncancerous breast epithelial cell line HBL-100. Results were presented as the mean ± SD. *P < 0.05 and *** P < 0.001